drugset / Trial / NCT06482853
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Phase 0
Recruiting
52 enrolled
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedCrossoverDouble-blindBasic science
Summary
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Timeline
- Start
- 2025-01-23
- Primary completion
- 2029-03
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | talfirastide | Peptide | 8 ng | Intravenous |